Physician profile
Tyler Basen
NPI 1184069692
$150,366.06
in general payments reported to CMS, 2019-2025
35 companies · $2,751 in 2025
The $2,751 reported for 2025 was more than what 78% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $669 · 2020: $3,092 · 2021: $3,470 · 2022: $2,094 · 2023: $101K · 2024: $37K · 2025: $2,751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $113K · Travel and Lodging: $19K · Food and Beverage: $8,763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $112,937.50 |
| Travel and Lodging | $19,340.50 |
| Food and Beverage | $8,763.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $136,808.53 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Genzyme Corporation | $3,579.23 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $2,520.05 | 2019-2024 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $1,217.55 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $935.57 | 2020-2025 | Cuvitru, Hyqvia, Takhzyro |
| Incyte Corporation | $812.95 | 2022-2025 | Opzelura |
| Pfizer INC. | $659.55 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $609.70 | 2019-2025 | |
| Leo Pharma INC. | $446.99 | 2023-2025 | Adbry |
| Octapharma USA, INC. | $405.50 | 2022-2025 | Cutaquig, Octagam Immune Globulin (Human) |
| Genentech USA, INC. | $314.20 | 2019-2025 | Xolair |
| Csl Behring | $236.99 | 2019-2025 | Hizentra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.69 | 2020-2022 | |
| Optinose US, INC. | $167.01 | 2022-2025 | |
| Alk-Abello, INC | $161.28 | 2019-2025 | Odactra, Grastek, Ragwitek |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $147.43 | 2025 | Streamline, Kahook Dual Blade, Via360 |
| Amgen INC. | $131.12 | 2022-2025 | Tezspire |
| Intuitive Surgical, INC. | $126.11 | 2025 | |
| Kaleo, INC. | $120.87 | 2020-2023 | Auvi-Q |
| Biocryst US Sales Co., LLC | $120.79 | 2022-2025 | Orladeyo |
| Galderma Laboratories, L.P. | $113.44 | 2025 | Nemluvio |
| Philips North America LLC | $92.77 | 2019-2020 | |
| Allergan, INC. | $74.54 | 2020 | |
| Abbvie INC. | $61.15 | 2023 | Rinvoq |
| Grifols USA, LLC | $56.18 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $38.61 | 2019-2021 | |
| Ionis Pharmaceuticals, INC. | $35.97 | 2025 | Dawnzera |
| Lilly USA, LLC | $29.66 | 2025 | Ebglyss |
| Cycle Pharmaceuticals INC | $27.52 | 2025 | Sajazir |
| Ars Pharmaceuticals Operations, INC. | $26.79 | 2025 | Neffy |
| Horizon Therapeutics Plc | $25.31 | 2020 | |
| Jubilant Hollisterstier LLC | $24.21 | 2021 | |
| Arcutis Biotherapeutics, INC. | $22.43 | 2025 | Zoryve |
| Shire North American Group INC | $19.16 | 2019 | |
| Organon LLC | $18.21 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Basen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.